𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations

✍ Scribed by Xiaohong Rose Yang; Ruth M. Pfeiffer; William Wheeler; Meredith Yeager; Stephen Chanock; Margaret A. Tucker; Alisa M. Goldstein

Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
86 KB
Volume
125
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

CDKN2A is a major susceptibility gene for cutaneous malignant melanoma (CMM), but the variable penetrance and clinical manifestations among mutation carriers suggest the existence of modifier factors. The goal of this study was to identify modifier genes for CMM in CMM‐prone families with or without CDKN2A mutations. We genotyped 537 individuals (107 CMM) from 28 families (19 CDKN2A+, 9 CDKN2A−) for 1,536 SNPs in 152 genes involved in DNA repair, apoptosis and immune response pathways. We used conditional logistic regression to account for family ascertainment and differences in disease prevalence among families. Pathway‐ and gene‐based permutation analyses were used to assess the risk of CMM associated with genes in the 5 pathways (DNA repair, apoptosis, TNF/NFκB, TH1:TH2 and other immune regulation). Our analyses identified some candidate genes such as FAS, BCL7A, CASP14, TRAF6, WRN, IL9, IL10RB, TNFSF8, TNFRSF9 and JAK3 that were associated with CMM risk (p < 0.01, gene‐based test). After correction for multiple comparisons, IL9 remained significant (Bonferroni p < 0.05). The effects of some genes were stronger in CDKN2A‐positive families (BCL7A and IL9), while some were stronger in CDKN2A‐negative families (BCL2L1). Our findings support the hypothesis that common genetic polymorphisms in DNA repair, apoptosis and immune response pathways may modify the risk of CMM in CMM‐prone families with or without CDKN2A mutations. Published 2009 UICC.

📜 SIMILAR VOLUMES

New founder germline mutations of CDKN2A
New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment
✍ Caroline Kannengiesser; Stéphane Dalle; Marie-Thérèse Leccia; Marie Françoise Av 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB 👁 1 views

## Abstract Germline mutations in the __CDKN2A__ gene have been shown to predispose individuals to cutaneous malignant melanoma. Here, we describe three melanoma‐prone families and one isolated patient affected by multiple melanoma who carried a tandem germline mutation of __CDKN2A__ at the nucleot

Germline mutation and large deletion ana
Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer
✍ Tadeusz Dębniak; Bohdan Górski; Rodney J. Scott; Cezary Cybulski; Krzysztof Mędr 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 75 KB 👁 2 views

## Abstract The __CDKN2A/ARF__ genes have been associated with increased risk of malignant melanoma (MM) in families with multiple members affected by disease and in families characterized by the constellation of breast cancer and MM. The exact contribution of __CDKN2A/ARF__ to disease risk remains

Functional, structural, and genetic eval
Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients
✍ Caroline Kannengiesser; Sharon Brookes; Anna Gutierrez del Arroyo; Danielle Pham 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB 👁 1 views

Germline mutations of the CDKN2A gene are found in melanoma-prone families and individuals with multiple sporadic melanomas. The encoded protein, p16(INK4A), comprises four ankyrin-type repeats, and the mutations, most of which are missense and occur throughout the entire coding region, can disrupt

Retention of the CDKN2A locus and low fr
Retention of the CDKN2A locus and low frequency of point mutations in primary and metastasic cutaneous malignant melanoma
✍ Anna Ruiz; Susana Puig; Michael Lynch; Teresa Castel; Xavier Estivill 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 124 KB 👁 2 views

CDKN2A has been found mutated in melanoma families which show linkage to chromosome 9p21. In contrast, a low mutation rate has been found in melanomas, suggesting that CDKN2A might not be the first target for mutation in the development of this type of tumour. To elucidate the role of the CDKN2A gen

Haplotype analysis of two recurrent CDKN
Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations
✍ Pamela M. Pollock; Nigel Spurr; Tim Bishop; Julia Newton-Bishop; Nelleke Gruis; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views

Germ-line mutations in CDKN2A have been shown to predispose to cutaneous malignant melanoma. We have identified 2 new melanoma kindreds which carry a duplication of a 24bp repeat present in the 5' region of CDKN2A previously identified in melanoma families from Australia and the United States. This

Loss of expression of the p16INK4/CDKN2
Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage
✍ Lauri Talve; Ilari Sauroja; Yrjö Collan; Kari Punnonen; Tauno Ekfors 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 155 KB 👁 2 views

The G 1 /S checkpoint of the cell cycle is regulated by p16, p53 and RB tumor suppressor genes. Loss of expression of the p16 INK4 tumor suppressor protein, the product of the CDKN2 gene, has been associated with a wide variety of human malignancies. Mutations, loss of heterozygosity and deletions o